99 related articles for article (PubMed ID: 26562248)
1. Combined Ang-2 and VEGF serum levels: holding hands as a new integral biomarker in non-small-cell lung cancers.
Coelho AL; Araújo AM; Gomes MP; Catarino RJ; Andrade EB; Lopes AM; Medeiros RM
Future Oncol; 2015; 11(24):3233-42. PubMed ID: 26562248
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.
Akın Kabalak P; Çiledağ A; Demir N; Çelik G; Yüksel C; Köycü G; Gökmen Öztuna D; Taner A; Kaya A; Kutlay H; Numanoğlu N; Savaş İ
Tuberk Toraks; 2015 Jun; 63(2):71-7. PubMed ID: 26167963
[TBL] [Abstract][Full Text] [Related]
3. Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study.
Naumnik W; Naumnik B; Niewiarowska K; Ossolinska M; Chyczewska E
Adv Exp Med Biol; 2013; 788():341-8. PubMed ID: 23835996
[TBL] [Abstract][Full Text] [Related]
4. Serum angiopoietin-2 as a clinical marker for lung cancer.
Park JH; Park KJ; Kim YS; Sheen SS; Lee KS; Lee HN; Oh YJ; Hwang SC
Chest; 2007 Jul; 132(1):200-6. PubMed ID: 17505039
[TBL] [Abstract][Full Text] [Related]
5. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
6. Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer in Patients with Solitary Pulmonary Nodules.
Xu C; Wang W; Wang Y; Zhang X; Yan J; Yu L
Ann Clin Lab Sci; 2016; 46(1):60-4. PubMed ID: 26927344
[TBL] [Abstract][Full Text] [Related]
7. Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer.
Park JH; Choi H; Kim YB; Kim YS; Sheen SS; Choi JH; Lee HL; Lee KS; Chung WY; Lee S; Park KJ; Hwang SC; Lee KB; Park KJ
Lung Cancer; 2009 Dec; 66(3):359-64. PubMed ID: 19339077
[TBL] [Abstract][Full Text] [Related]
8. Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC.
Sun YH; Song PY; Guo Y; Pang M; He WN; Zhang WH; Sheng LJ
Genet Mol Res; 2015 Aug; 14(3):10015-25. PubMed ID: 26345938
[TBL] [Abstract][Full Text] [Related]
9. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
10. Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].
Coelho AL; Araújo A; Gomes M; Catarino R; Marques A; Medeiros R
PLoS One; 2014; 9(2):e90009. PubMed ID: 24587185
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2.
Andersen S; Donnem T; Al-Shibli K; Al-Saad S; Stenvold H; Busund LT; Bremnes RM
PLoS One; 2011; 6(5):e19773. PubMed ID: 21603628
[TBL] [Abstract][Full Text] [Related]
12. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C
Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963
[TBL] [Abstract][Full Text] [Related]
13. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
Hu Y; Hu MM; Shi GL; Han Y; Li BL
Eur J Surg Oncol; 2014 Sep; 40(9):1136-42. PubMed ID: 24998915
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.
Xuan ZX; Zhang S; Yuan SJ; Wang W; Yu J
World J Surg Oncol; 2016 Sep; 14(1):237. PubMed ID: 27589869
[TBL] [Abstract][Full Text] [Related]
15. Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer.
Li M; Zhang Q; Wu L; Jia C; Shi F; Li S; Peng A; Zhang G; Song X; Wang C
Oncol Rep; 2014 Apr; 31(4):1961-7. PubMed ID: 24549225
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.
Naumnik W; Nilklińska W; Ossolińska M; Chyczewska E
Folia Histochem Cytobiol; 2009; 47(4):703-9. PubMed ID: 20430742
[TBL] [Abstract][Full Text] [Related]
17. Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer.
Lee SH; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
Lung Cancer; 2014 Aug; 85(2):175-81. PubMed ID: 24951318
[TBL] [Abstract][Full Text] [Related]
18. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer.
Shimanuki Y; Takahashi K; Cui R; Hori S; Takahashi F; Miyamoto H; Fukurchi Y
Lung; 2005; 183(1):29-42. PubMed ID: 15793665
[TBL] [Abstract][Full Text] [Related]
19. [The evaluation to relationship between serum vascular endothelial growth factor (VEGF) level, metastases and other tumor markers in patients with lung cancer].
Sağlam DA; Ursavaş A; Karadağ M; Yilmaztepe Oral A; Coşkun F; Gözü RO
Tuberk Toraks; 2008; 56(1):50-5. PubMed ID: 18330755
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy.
Naumnik W; Chyczewska E; Ossolinska M
Cancer Invest; 2009 Aug; 27(7):741-6. PubMed ID: 19340656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
